Snapshot from Sep 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory action

India flags Abhayrab batch as substandard

Analysis based on 14 articles · First reported Sep 04, 2026 · Last updated Sep 05, 2026

Sentiment
-30
Attention
4
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The regulatory action could undermine confidence in Indian Immunologicals' vaccine quality, potentially affecting its domestic market share and export reputation. The company may face increased scrutiny and potential financial losses if the batch is confirmed spurious, though the immediate impact is limited as the company has not responded and the investigation is ongoing.

Pharmaceuticals Healthcare

India's drug regulator, the India — Central Drugs Standard Control Organisation, has flagged a batch of the rabies vaccine Abhayrab, manufactured by Indian Immunologicals Limited, as substandard and potentially spurious after it failed a potency test. The action, detailed in an August 27 letter from Drugs Controller General Rajeev Singh Raghuvanshi to state regulators, followed a finding by the India — Central Drugs Laboratory in Kasauli that a field sample of batch KE25012 did not meet potency requirements and was classified as 'not of standard quality' and 'misbranded'. The laboratory also noted significant discrepancies in labelling, artwork, QR code verification, cap colour, licence details, and packaging text compared to a retained reference sample, raising concerns about the sample's identity and authenticity. The regulator has ordered an investigation into whether the batch could be a spurious drug under India's Drugs and Cosmetics Act. This is the second such incident in less than two years; in January 2025, Indian Immunologicals had notified the regulator about counterfeit Abhayrab doses bearing batch number KA24014, which led to alerts from health authorities in the United States, United Kingdom, and Australia for travellers who may have received the vaccine in India. Indian Immunologicals has supplied over 210 million doses of Abhayrab over two decades and holds a 40% share of the domestic rabies vaccine market. The company exports to more than 40 countries, including South Africa, Turkey, Vietnam, Cambodia, Zimbabwe, Thailand, and the United Arab Emirates. The government document does not state how many doses of the flagged batch were distributed or whether any were exported.

priv
The manufacturer of Abhayrab faces regulatory scrutiny and potential reputational damage from the flagged batch. This is the second counterfeit-related incident in two years, which could affect its market position and export business.
Importance 100.0 Sentiment -40.0
govactor
The regulator flagged the batch and ordered an investigation, demonstrating vigilance. Its actions may enhance its credibility but also highlight challenges in monitoring counterfeit drugs.
Importance 90.0 Sentiment 10.0
cnt
India's drug regulatory system is under the spotlight as it investigates a potentially spurious batch of a widely used vaccine. The country's high rabies burden makes vaccine safety critical.
Importance 80.0 Sentiment -20.0
govactor
The laboratory's testing identified the potency failure and discrepancies, triggering the regulatory action.
Importance 70.0 Sentiment 0.0
per
As Drugs Controller General, he issued the letter to state regulators, playing a key role in the regulatory response.
Importance 60.0 Sentiment 0.0
cnt
US health authorities previously issued alerts for travellers regarding counterfeit Abhayrab doses, reflecting international concern.
Importance 30.0 Sentiment -10.0
cnt
UK health authorities previously issued alerts for travellers regarding counterfeit Abhayrab doses.
Importance 30.0 Sentiment -10.0
cnt
Australian health authorities previously issued alerts for travellers regarding counterfeit Abhayrab doses.
Importance 30.0 Sentiment -10.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
cnt
One of the export destinations for Abhayrab; potential impact if the flagged batch was exported.
Importance 10.0 Sentiment -5.0
India strategic partners ↔ United States India views the United States as a key strategic and economic partner, engaging in defense cooperation and significant t
India related ↔ United Kingdom
India related ↔ Australia
India related ↔ Thailand
India related ↔ Turkey
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
United States related ↔ Australia
United States related ↔ Thailand
United States related ↔ Turkey
United Kingdom allies ↔ Australia The United Kingdom considers Australia a vital strategic partner in the Indo-Pacific, bound by the AUKUS nuclear submari
United Kingdom related ↔ Thailand
United Kingdom related ↔ Turkey
Australia related ↔ Thailand
Australia related ↔ Turkey
+ 1 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.